journal
MENU ▼
Read by QxMD icon Read
search

Journal of Pharmaceutical Policy and Practice

journal
https://www.readbyqxmd.com/read/28405339/ethiopian-patients-perceptions-of-anti-diabetic-medications-implications-for-diabetes-education
#1
Bruck Messele Habte, Tedla Kebede, Teferi Gedif Fenta, Heather Boon
BACKGROUND: The purpose of this study is to explore medication-related perceptions of adult patients with type 2 diabetes attending treatment in public hospitals of urban centers in central Ethiopia. METHODS: Qualitative in-depth interviews were held with 39 participants selected to represent a range of treatment experiences and socio-demographic characteristics who were attending their treatment in 3 public hospitals. Interviews continued until key themes were saturated...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28392925/antibiotic-knowledge-attitudes-and-behaviours-of-albanian-health-care-professionals-and-patients-a-qualitative-interview-study
#2
Susanne Kaae, Admir Malaj, Iris Hoxha
BACKGROUND: The inappropriate use of antimicrobials is a problem worldwide. To target future interventions, a thorough understanding of the reasons behind this current behaviour is needed. Within the EU, the culture of antimicrobial use has been intensely studied, but this is not the case in non-EU southeastern European countries, despite the frequent use of (broad-spectrum) antibiotics (ABs) in this region. The aim of this study was to explore AB knowledge, attitudes and behaviours of health care professionals (HCPs) and patients in one southeastern European country, Albania...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28331624/comparison-of-hydroxyethyl-starch-regulatory-summaries-from-the-food-and-drug-administration-and-the-european-medicines-agency
#3
Christian J Wiedermann, Klaus Eisendle
This article aims to highlight the positions of the Food and Drug Administration and the European Medicines Agency regarding use and marketing of hydroxyethyl starch (HES) products, and how these have changed over recent years. In 2013, warnings from both agencies advised against use of HES in critically ill patients, including patients with sepsis, when several large randomized controlled trials on volume resuscitation in critical illness failed to observe clinically beneficial effects of HES. In areas such as patient monitoring and requirements for further clinical trials, the FDA and EMA are very much in agreement in their recommendations...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28261487/drug-pricing-and-reimbursement-decision-making-systems-in-mongolia
#4
Gereltuya Dorj, Bruce Sunderland, Tsetsegmaa Sanjjav, Gantuya Dorj, Byambatsogt Gendenragchaa
BACKGROUND: It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently, transparent and evidence based research is required to evaluate decision making regarding drug registration, drug pricing and reimbursement processes in Mongolia. OBJECTIVE: To assess the drug reimbursement system and discuss challenges faced by policy-makers and stakeholders...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28250958/capacity-for-ethical-and-regulatory-review-of-herbal-trials-in-developing-countries-a-case-study-of-moringa-oleifera-research-in-hiv-infected-patients
#5
Tsitsi G Monera-Penduka, Charles C Maponga, Gene D Morse, Charles F B Nhachi
BACKGROUND: Lack of regulatory capacity limits the conduct of ethical and rigorous trials of herbal medicines in developing countries. Sharing ethical and regulatory experiences of successful herbal trials may accelerate the field while assuring human subjects protection. The methods and timelines for the ethical and regulatory review processes for the first drug regulatory authority approved herbal trial in Zimbabwe are described in this report. METHODS: The national drug regulatory authority and ethics committee were engaged for pre-submission discussions...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28239479/the-changing-landscape-of-expanded-access-to-investigational-drugs-for-patients-with-unmet-medical-needs-ethical-implications
#6
EDITORIAL
Eline M Bunnik, Nikkie Aarts, Suzanne van de Vathorst
When patients are told that standard medical treatment options have been exhausted, their treating physicians may start looking for promising new drugs that are not yet approved, and still under investigation. Some patients can be included in clinical trials, but others cannot. It is not widely known that these patients might still be eligible for trying investigational drugs, in a therapeutic context. Worldwide, public and private parties are seeking to change this by informing patients and physicians about opportunities for expanded access and/or by facilitating its processes...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28191318/structured-pharmaceutical-care-improves-the-health-related-quality-of-life-of-patients-with-asthma
#7
Philip O Anum, Berko P Anto, Audrey G Forson
BACKGROUND: Asthma as a chronic health condition can be controlled when in addition to clinical care, adequate education and support is provided to enhance self-management. Like many other chronic health conditions improved self-management positively impacts the health-related quality of life (HRQoL). It can therefore be said that a well-structured pharmaceutical care delivery that addresses the issues related to patient education and support towards self-management stands a good chance of positively impacting asthma control...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28116107/prices-and-availability-of-locally-produced-and-imported-medicines-in-ethiopia-and-tanzania
#8
M Ewen, W Kaplan, T Gedif, M Justin-Temu, C Vialle-Valentin, Z Mirza, B Regeer, M Zweekhorst, R Laing
BACKGROUND: To assess the effect of policies supporting local medicine production to improve access to medicines. METHODS: We adapted the WHO/HAI instruments measuring medicines availability and prices to differentiate local from imported products, then pilot tested in Ethiopia and Tanzania. In each outlet, prices were recorded for all products in stock for medicines on a country-specific list. Government procurement prices were also collected. Prices were compared to an international reference and expressed as median price ratios (MPR)...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28116106/engagement-of-the-private-pharmaceutical-sector-for-tb-control-rhetoric-or-reality
#9
Niranjan Konduri, Emily Delmotte, Edmund Rutta
BACKGROUND: Private-sector retail drug outlets are often the first point of contact for common health ailments, including tuberculosis (TB). Systematic reviews on public-private mix (PPM) interventions for TB did not perform in-depth reviews specifically on engaging retail drug outlets and related stakeholders in the pharmaceutical sector. Our objective was to better understand the extent to which the World Health Organization's (WHO) recommendation on engaging retail drug outlets has been translated into programmatic policy, strategy, and intervention in low- and middle-income countries...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28070340/civil-society-engagement-in-multi-stakeholder-dialogue-a-qualitative-study-exploring-the-opinions-and-perceptions-of-meta-members
#10
Gemma L Buckland-Merrett, Catherine Kilkenny, Tim Reed
BACKGROUND: The Medicines Transparency Alliance (MeTA) is an initiative that brings together all stakeholders in the medicines market to create a multi-stakeholder dialogue and improve access, availability and affordability of medicines. Key to this multi-stakeholder dialogue is the participation of Civil Society Organisations. A recent MeTA annual review, identified uneven engagement of civil society organisations in the multi-stakeholder process. This study was designed to explore the engagement of Civil Society Organisations in the MeTA multi-stakeholder process and the factors influencing their participation...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28070339/approval-status-and-evidence-for-who-essential-medicines-for-children-in-the-united-states-united-kingdom-and-japan-a-cross-sectional-study
#11
Rumiko Shimazawa, Masayuki Ikeda
BACKGROUND: The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but usually focuses on diseases common in those countries and not in low- and middle-income countries. METHODS: This cross-sectional study assessed supporting evidence for the 346 medicines in the 5th WHO EMLc and their approval data from the United States, United Kingdom, and Japan...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27446593/the-global-intellectual-property-ecosystem-for-insulin-and-its-public-health-implications-an-observational-study
#12
Warren A Kaplan, Reed F Beall
BACKGROUND: Lack of access to insulin and poor health outcomes are issues for both low and high income countries. This has been accompanied by a shift from relatively inexpensive human insulin to its more expensive analogs, marketed by three to four main global players. Nonetheless, patent-based market exclusivities are beginning to expire there for the first generation insulin analogs. This paper adds a global dimension to information on the U.S. patent landscape for insulin by reviewing the patent status of insulins with emphasis on the situation outside the US and Europe...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27446592/economic-contributions-of-pharmaceutical-interventions-by-pharmacists-a-retrospective-report-in-japan
#13
Daiki Yasunaga, Yuichi Tasaka, Satoshi Murakami, Akihiro Tanaka, Mamoru Tanaka, Hiroaki Araki
BACKGROUND: Pharmacists in Japan currently play a key role in patient hospital care. Their responsibilities include filling prescriptions, checking a patient's medication history, and providing appropriate information to other health care workers. More importantly, pharmacists' interventions can also result in reductions in adverse drug reactions (ADRs) and, ultimately, in cost savings. This study aimed to determine the economic value of such interventions at a hospital in Japan. METHODS: At a single Japanese hospital, we analyzed 1452 pharmaceutical interventions by pharmacists, including recommending antibiotic dosage regimens, attending ward rounds with multidisciplinary health providers, providing drug information, and reporting ADRs...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27446591/assessment-of-current-prescribing-practices-using-world-health-organization-core-drug-use-and-complementary-indicators-in-selected-rural-community-pharmacies-in-southern-india
#14
Anandhasayanam Aravamuthan, Mohanavalli Arputhavanan, Kannan Subramaniam, Sam Johnson Udaya Chander J
BACKGROUND: Due to the lack of clear, comprehensive, and rational drug policy, the production of pharmaceutical preparations in India is distorted for the most part. Indian markets are flooded with more than 70,000 formulations, compared to approximately 350 formulations listed in the World Health Organization (WHO) Essential Drug List. Studies have indicated that majority of prescriptions in India are of drugs of "doubtful efficacy." To promote rational drug use in developing countries, assessment of drug use patterns with the WHO drug use indicators is becoming increasingly necessary...
2017: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/28050254/the-choice-between-a-ritonavir-boosted-protease-inhibitor-and-a-non-nucleoside-reverse-transcriptase-inhibitor-based-regimen-for-initiation-of-antiretroviral-treatment-results-from-an-observational-study-in-germany
#15
Jörg Mahlich, Mona Groß, Alexander Kuhlmann, Johannes Bogner, Hans Heiken, Matthias Stoll
BACKGROUND: This study aims at identifying predictors of the treatment decision of German physicians with regard to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r) -based initial treatment regimen. METHODS: The study is based on a sub analysis of a nation-wide multi-centre, non-interventional, prospective cohort study. 133 patients were identified, who received antiretroviral first-line therapy. By means of a logistic regression, factors that determine the treatment strategy for treatment-naïve patients were analysed...
2016: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27933178/assessing-medication-packaging-and-labelling-appropriateness-in-sri-lanka
#16
N Athuraliya, E J Walkom, S Dharmaratne, J Robertson
BACKGROUND: There is substantial evidence of poor dispensing practices with inadequate packaging and labelling of medicines, and limited advice on their usage in low and middle-income countries (LMICs). We examined the labelling and packaging of medicines identified during a survey of 1322 households in six regions of Sri Lanka between 2010 and 2013 conducted using the World Health Organization (WHO) methodology for household surveys. We compared medicines obtained from public and private sources and asked interviewees if they understood how to take the medicines...
2016: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27891235/interaction-and-medical-inducement-between-pharmaceutical-representatives-and-physicians-a-meta-synthesis
#17
REVIEW
Shahrzad Salmasi, Long Chiau Ming, Tahir Mehmood Khan
BACKGROUND: It has been proven that the interaction between pharmaceutical representatives and physicians can directly influence the latter's prescribing behaviour. This meta-synthesis aims to explore the available studies regarding the nature of the interaction that takes place between pharmaceutical representatives and physicians. It highlights the different aspects of that interaction by investigating the reasons why these meetings happen in the first place, their benefits and drawbacks and their impact on patients' health and, ultimately, the health of the public...
2016: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27843547/fighting-poor-quality-medicines-in-low-and-middle-income-countries-the-importance-of-advocacy-and-pedagogy
#18
EDITORIAL
Raffaella Ravinetto, Daniel Vandenbergh, Cécile Macé, Corinne Pouget, Brigitte Renchon, Jean Rigal, Benedetta Schiavetti, Jean-Michel Caudron
The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries...
2016: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27800166/an-assessment-of-the-future-impact-of-alternative-technologies-on-antibiotics-markets
#19
Ejike Nwokoro, Ross Leach, Christine Årdal, Enrico Baraldi, Kellie Ryan, Jens Plahte
BACKGROUND: The increasing threat of antimicrobial resistance combined with the paucity of new classes of antibiotics represents a serious public health challenge. New treatment technologies could, in theory, have a significant impact on the future use of traditional antibiotics, be it by facilitating rational and responsible use or by product substitution in the existing antibiotics markets, including by reducing the incidence of bacterial infections through preventative approaches. The aim of this paper is to assess the potential of alternative technologies in reducing clinical use of and demand for antibiotics, and to briefly indicate which segments of the antibiotics market that might be impacted by these technologies...
2016: Journal of Pharmaceutical Policy and Practice
https://www.readbyqxmd.com/read/27800165/medicine-and-the-future-of-health-reflecting-on-the-past-to-forge-ahead
#20
EDITORIAL
Dale Fisher, Paul Wicks, Zaheer-Ud-Din Babar
The development of new therapies has a rich history, evolves quickly with societal trends, and will have an exciting future. The last century has seen an exponential increase in complex interactions between medical practitioners, pharmaceutical companies, governments and patients. We believe technology and societal expectations will open up the opportunity for more individuals to participate as information becomes more freely available and inequality less acceptable. Corporations must recognize that usual market forces do not function ideally in a setting where health is regarded as a human right, and as modern consumers, patients will increasingly take control of their own data, wellbeing, and even the means of production for developing their own treatments...
2016: Journal of Pharmaceutical Policy and Practice
journal
journal
48346
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"